Login
$RZLT
$3.53 -$0.05 (1.4%) After hours

$RZLT SEC Filings

Filed On Filing
16 Nov 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

13 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G
13 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation

13 Nov 2026 FWP
13 Nov 2026 424B5
10 Nov 2026 EFFECT
05 Nov 2026 S-3
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

REDWOOD CITY, Calif., November 5, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), ...

29 Oct 2026 8-K: Regulation FD Disclosure

A Late - stage Ultra - rare Disease Company Treating Refractory Hypoglycemia Corporate Presentation

28 Oct 2026 SCHEDULE 13G
23 Oct 2026 Form 4: Evans Daron, CFO

Gave 16,000 shares as a gift · Acquired 8,000 shares (Gift)

21 Oct 2026 Proxy statement: annual meeting on December 2, 2026

CEO pay $5.7M, up 100% · say-on-pay vote

15 Oct 2026 DRS
14 Oct 2026 8-K: Regulation FD Disclosure

REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced...

07 Oct 2026 PRE 14A
05 Oct 2026 8-K: Regulation FD Disclosure

The Agency reiterated its commitment to addressing the unmet need for treatment

24 Sep 2026 10-K
24 Sep 2026 8-K: Results of Operations and Financial Condition

REDWOOD CITY, Calif., September 24, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support